US › Healthcare

Lucid Diagnostics Inc (LUCD)

US · Healthcare · Medical Devices

$0.78-6.70%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.5M

Revenue YoY

+26.7%

Net profit

$-11.7M

EPS

$-0.08

EPS estimate

$-0.05

Net margin

-792.9%

EPS came in at -0.08 against a street estimate of -0.05 — a miss of 60.0%.

Key statistics

Market cap

$159.7M

Forward P/E

0.0

P/B

13.84

Book value

$0.06

EPS (TTM)

$-0.41

52-week high

$1.63

52-week low

$0.75

50-day MA

$0.95

200-day MA

$1.11

Beta

1.10

Analyst view

Analysts rate Lucid Diagnostics Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $4.00.

Shareholding

Insiders

26.50%

Institutions

33.37%

Largest institutional holders

Fund	Stake
BlackRock Inc	2.43%
Vanguard Capital Management, LLC	2.18%
Masters Capital Management LLC	2.09%
Aberdeen Group PLC	2.00%
Two Seas Capital LP	1.57%
Geode Capital Management, LLC	1.18%
State Street Corp	0.81%
Wells Fargo & Co	0.67%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lucid Diagnostics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.